BACKGROUND: The Src tyrosine kinase substrate and adaptor protein Tks5 had previously been implicated in the invasive phenotype of normal and transformed cell types via regulation of cytoskeletal structures called podosomes/invadopodia. The role of Src-Tks5 signaling in invasive prostate cancer, however, had not been previously evaluated. METHODS: We measured the relative expression of Tks5 in normal (n = 20) and cancerous (n = 184, from 92 patients) prostate tissue specimens by immunohistochemistry using a commercially available tumor microarray. We also manipulated the expression and activity of wild-type and mutant Src and Tks5 constructs in the LNCaP and PC-3 prostate cancer cell lines in order to ascertain the role of Src-Tks5 signaling in invadopodia development, matrix-remodeling activity, motility, and invasion. RESULTS: Our studies demonstrated that Src was activated and Tks5 upregulated in high Gleason score prostate tumor specimens and in invasive prostate cancer cell lines. Remarkably, overexpression of Tks5 in LNCaP cells was sufficient to induce invadopodia formation and associated matrix degradation. This Tks5-dependent increase in invasive behavior further depended on Src tyrosine kinase activity and the phosphorylation of Tks5 at tyrosine residues 557 and 619. In PC-3 cells we demonstrated that Tks5 phosphorylation at these sites was necessary and sufficient for invadopodia-associated matrix degradation and invasion. CONCLUSIONS: Our results suggest a general role for Src-Tks5 signaling in prostate tumor progression and the utility of Tks5 as a marker protein for the staging of this disease.
BACKGROUND: The Srctyrosine kinase substrate and adaptor protein Tks5 had previously been implicated in the invasive phenotype of normal and transformed cell types via regulation of cytoskeletal structures called podosomes/invadopodia. The role of Src-Tks5 signaling in invasive prostate cancer, however, had not been previously evaluated. METHODS: We measured the relative expression of Tks5 in normal (n = 20) and cancerous (n = 184, from 92 patients) prostate tissue specimens by immunohistochemistry using a commercially available tumor microarray. We also manipulated the expression and activity of wild-type and mutant Src and Tks5 constructs in the LNCaP and PC-3prostate cancer cell lines in order to ascertain the role of Src-Tks5 signaling in invadopodia development, matrix-remodeling activity, motility, and invasion. RESULTS: Our studies demonstrated that Srcwas activated and Tks5 upregulated in high Gleason score prostate tumor specimens and in invasive prostate cancer cell lines. Remarkably, overexpression of Tks5 in LNCaP cells was sufficient to induce invadopodia formation and associated matrix degradation. This Tks5-dependent increase in invasive behavior further depended on Srctyrosine kinase activity and the phosphorylation of Tks5 at tyrosine residues 557 and 619. In PC-3 cells we demonstrated that Tks5 phosphorylation at these sites was necessary and sufficient for invadopodia-associated matrix degradation and invasion. CONCLUSIONS: Our results suggest a general role for Src-Tks5 signaling in prostate tumor progression and the utility of Tks5 as a marker protein for the staging of this disease.
Authors: Darren F Seals; Eduardo F Azucena; Ian Pass; Lia Tesfay; Rebecca Gordon; Melissa Woodrow; James H Resau; Sara A Courtneidge Journal: Cancer Cell Date: 2005-02 Impact factor: 31.743
Authors: Oleg Tatarov; Thomas J Mitchell; Morag Seywright; Hing Y Leung; Valerie G Brunton; Joanne Edwards Journal: Clin Cancer Res Date: 2009-05-15 Impact factor: 12.531
Authors: Mirela Goldenberg-Furmanov; Ilan Stein; Eli Pikarsky; Hila Rubin; Shafika Kasem; Marc Wygoda; Irina Weinstein; Hadas Reuveni; Shmuel A Ben-Sasson Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Xiang H-F Zhang; Qiongqing Wang; William Gerald; Clifford A Hudis; Larry Norton; Marcel Smid; John A Foekens; Joan Massagué Journal: Cancer Cell Date: 2009-07-07 Impact factor: 31.743
Authors: Oliver Thompson; Iivari Kleino; Luca Crimaldi; Mario Gimona; Kalle Saksela; Steve J Winder Journal: PLoS One Date: 2008-11-04 Impact factor: 3.240
Authors: Lizandra Jimenez; Ved P Sharma; John Condeelis; Thomas Harris; Thomas J Ow; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall Journal: Arch Pathol Lab Med Date: 2015-07-14 Impact factor: 5.534
Authors: Shinji Iizuka; Manuela Quintavalle; Jose C Navarro; Kyle P Gribbin; Robert J Ardecky; Matthew M Abelman; Chen-Ting Ma; Eduard Sergienko; Fu-Yue Zeng; Ian Pass; George V Thomas; Shannon K McWeeney; Christian A Hassig; Anthony B Pinkerton; Sara A Courtneidge Journal: Cancer Res Date: 2021-01-07 Impact factor: 13.312
Authors: Barbara Blouw; Manishha Patel; Shinji Iizuka; Christopher Abdullah; Weon Kyoo You; Xiayu Huang; Jian-Liang Li; Begoña Diaz; William B Stallcup; Sara A Courtneidge Journal: PLoS One Date: 2015-03-31 Impact factor: 3.240
Authors: Myles C Hodgson; Elena I Deryugina; Egla Suarez; Sandra M Lopez; Dong Lin; Hui Xue; Ivan P Gorlov; Yuzhuo Wang; Irina U Agoulnik Journal: Cell Commun Signal Date: 2014-09-25 Impact factor: 5.712